JPRN-UMIN000010850
Recruiting
未知
Japan registry to use of Promus element in acute coronary syndrome patients - J-POSEIDON registry
Society of ACS Intervention and Therapeutics0 sites500 target enrollmentJune 1, 2013
ConditionsAcute Coronary Syndrome
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Acute Coronary Syndrome
- Sponsor
- Society of ACS Intervention and Therapeutics
- Enrollment
- 500
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •F)Enrolled in another study (excluding PMS) or receiving any treatment affected the registry. G)Pregnant or possibility of pregnancy in the registry period. H)Known hypersensitivity reaction to everolimus, polymer, metal I)Known hypersensitivity reaction to antiplatelet J)Improper functioning of the liver K)Kidney malfunction(\>\=3\.0mg/dl serum creatinine level) or dialysis treatment. L)Active cancer M)Lesion in saphenous vein graft N)cardiogenic shock by clinical assessment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Japanese registry of primary prevention implantable cardioverter defibrillator in heart failure patientsHeart failure patients with primary prevention implantable cardioverter defibrillatorJPRN-UMIN000051757Tokyo Women's Medical University1,500
Completed
Not Applicable
Japan Prosthetic Valve Registrypost prosthetic valve replacementJPRN-UMIN000013617Academic committee of Japanese society of Echocardiography300
Recruiting
Not Applicable
Japan Apheresis RegistryAny Conditions Requiring Therapeutic ApheresisJPRN-UMIN000039498Japanese Society for Apheresis10,000
Completed
Phase 3
Long-Term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional DyspepsiaDyspepsiaNCT00112203Forest Laboratories466
Recruiting
Not Applicable
J-REGISTER: Japanese REal-world data for treatment of afatinib (GIotrif) in first-line setting and Subsequent Therapies for patients with advanced EGFR mutation-positive lung adenocarcinomaJPRN-UMIN000044071ippon Boehringer Ingelheim Co., Ltd.1,000